TusTalks -- Talk with Sir Gregory Winter

Sir Gregory Winter spent almost all of this research career at the MRC laboratory of Molecular Biology Cambridge (LMB), where he undertook and developed technologies that led to several blockbuster antibody drugs, including Humira, Keytruda, Avastin, and Herceptin. For his work on antibody phage display he shared the Nobel Prize in Chemistry in 2018. In parallel with his research, he immersed himself in commercial matters, including the filing of patents, the development of licensing strategies and the founding of start-up companies.

At the LMB he became Head of the Division of Protein and Nucleic Acid Chemistry, and Deputy Director. In 2012 he was appointed as Master of Trinity College, stepping down in 2019. Now in retirement, he serves as a non-executive Director of the company Bicycle Therapeutics (NASDAQ: BCYC), which he founded for the development of small bicyclic peptides as antibody mimics.